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Summary Serum activity of ax-N-acetylgalactosaminidase (NaGalase), the extracellular matrix-degrading enzyme that appears to be
produced exclusively by cancer cells, was measured in mice bearing SCCVII tumours (squamous cell carcinoma). The NaGalase levels in
these mice increased with time of tumour growth and were directly proportional to tumour burden. After exposure of SCCVII tumours to a
single X-ray dose of 20 Gy, the serum NaGalase levels gradually decreased during the first 10 days aftertreatment (to approximately one-third
of the initial value) and then began to increase. The decrease in serum NaGalase activity was more rapid after the treatment of SCCVII and
EMT6 tumours by photodynamic therapy (PDT) and was dependent on the PDT dose. The treatments (based on photosensitizers Photofrin
or mTHPC) that were fully curative resulted in the reduction of NaGalase activity to background levels within 2 or 3 days after PDT. A slower
decrease in NaGalase activity was found after PDT treatments that attain an initial tumour ablation but are not fully curative. The regrowth of
PDT-treated SCCVII tumours was preceded by an increase in serum NaGalase levels, which was detected as early as 8 days before the
visible tumour reappearance. These findings ascertain the validity of serum NaGalase measurement for the assessment of tumour response
to different treatments and support the concept that the NaGalase measurement could serve as a diagnostic and prognostic index that might
allow oncologists to design the dosage or nature of treatment.
Keywords: mouse tumour models; a-N-acetylgalactosaminidase; cancer-specific enzyme; prognostic index; radiotherapy; photodynamic
therapy; tumour response indicator
a-N-Acetylgalactosaminidase (NaGalase) appears to be one of
the extracellular matrix-degrading enzymes secreted by cancerous
cells in the process of tumour invasion. The activity of NaGalase
can be detected in the bloodstream of patients bearing a wide
variety ofcancers but not in the blood ofhealthy humans. In addi-
tion to the types of cancer (i.e. prostate, breast and colon) refer-
enced in Yamamoto et al (1996), elevated NaGalase activity was
detected indiscriminately in all examined cases of mesothelioma,
melanoma, fibrosarcoma, glioblastoma, neuroblastoma, cancers of
lung, oesophagus, stomach, liver, pancreas, kidney, bladder, testis,
uterus and ovary and various leukaemias (in total 420 patients
examined thus far). The progression ofradiation therapy in cancer
patients is accompanied with a gradual decrease in NaGalase
levels in their blood (Yamamoto et al, 1996), presumably
reflecting a decrease in the number of cancerous cells secreting
this enzyme. Studies correlating serum NaGalase levels with
tumour burden suggest that the measurement of this enzyme can
diagnose the presence ofcancerous lesions below levels detectable
by other diagnostic means (Yamamoto et al, 1996; 1997a;
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Yamamoto and Naraparaju, 1997). These findings led to the
suggestion that the NaGalase activity in a patient's bloodstream
can serve as a diagnostic and prognostic index (Yamamoto et al,
1996; 1997a; Yamamoto, 1997).
NaGalase secreted into patient's blood deglycosylates the
vitamin D3-binding protein (DBP; human DBP is known as Gc
protein), a serum protein that is the precursor for the major
macrophage-activating factor (MAF) (Yamamoto et al, 1996;
1997a). The deglycosylated DBP cannot be converted to MAF.
The progress ofmalignant disease was found to be associated with
an increase in the serum NaGalase activity and a concomitant
decrease in the precursor activity of serum DBP (Yamamoto et al,
1996; 1997a; Yamamoto and Naraparaju, 1997). As macrophage
activation for phagocytosis and antigen presentation is the first
step in the immune development cascade, lost or reduced
precursor activity leads to immunosuppression (Yamamoto et al,
1996; 1997a).
Studies using mouse tumour models have demonstrated that
there is a direct correlation between the serum NaGalase levels and
growth rate ofboth non-solid tumours (Ehrlich ascites growing in
the peritoneal cavity) (Yamamoto and Naraparaju, 1997) and solid
tumours (human squamous cell carcinoma KB in nude mice)
(Yamamoto et al, 1997a). The objective ofthe present study was to
investigate how the response of tumours to radiotherapy and
photodynamic therapy (PDT) is reflected in the serum NaGalase
activity ofthe hosts.
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MATERIALS AND METHODS
Tumour models and treatments
Murine squamous cell carcinoma SCCVII (Suit et al, 1985) and
mammary sarcoma EMT6 (Rockwell et al, 1972) were maintained
in syngeneic C3H/HeN and BALB/c mice respectively, as
described in detail elsewhere (Korbelik, 1993; Korbelik and Krosl,
1996). For tumour implantation, 1 x 106 tumour cells were inocu-
lated subcutaneously in the lower dorsal region of 8- to 11-week-
old female mice.
Tumours were treated with X-rays when they reached a volume
of approximately 50 mm3. The mice were restrained, unanaes-
thetized in lead holders that shielded their body while fully
exposing the tumour to the X-ray beam. The source of irradiation
was a Philips RT250 (250 kV, 0.5 mm Cu), and the dose delivered
was 20 Gy at 3.33 Gy min-m. To ensure a uniform dose throughout
the tumour volume, the mice were turned 1800 mid-way through
irradiation. Monitoring the changes in tumour volume after the
X-ray treatment was based on measuring three orthogonal tumour
diameters. The treatment group consisted of 18 mice.
The photosensitizers Photofrin porfimer sodium (provided by
QLT PhotoTherapeutics, Vancouver, BC, Canada) and meta-
tetrahydroxyphenylchlorin (mTHPC; provided by Scotia Pharma-
ceuticals, Surrey, UK) were used for PDT. Stock solutions of
Photofrin (in 5% dextrose) and mTHPC (dissolved in ethanol-
PEG400-water at 1:1:1 volume ratios) were injected intravenously
24 h before the light treatment. Mice, restrained unanaesthetized in
the same holders as for X-ray irradiation, were treated with light
(630 ± 10 nm for Photofrin or 652 ± 10 nm for mTHPC) delivered
from a tunable light source based on a 1-kW xenon bulb (Model A
5000; Photon Technology International) through a 5-mm-core
diameter liquid light guide (2000 A; Luminex, Munich, Germany).
The powerdensity at the illuminated areaencompassing the tumour
and 1 mm of surrounding normal tissue was 120-130 mW cm-2
with Photofrin PDT and 110-120 mW cm-2 with mTHPC PDT.
The PDT doses used (55-110 J cm-2) were either fully curative or
yielded cures in the range 10-50%, with illumination times ranging
between 10 and 20 min. The treated tumours were ofthe same size
as those exposed to X-rays.
All tumour-bearing mice used in a particular experiment
received the same PDT treatment, except in the experiment with
two different light treatments (Figure 3B). The mice were divided
into groups (3-6 animals) that were used for the collection of
blood at different time intervals after PDT.
Measurement of tumour burden
Blood for the NaGalase activity measurement was collected from
the tail vein of mice immediately before they were killed, and the
wet weight of the excised tumours was determined (Yamamoto et
al, 1997a). In experiments presented in Figure 4B, multiple blood
collections (not more than 0.1 ml each time) were performed for
an extended time period after the tumour treatment. The interval
between the two blood withdrawals from the same mouse was
10 days or longer. No influence on tumour response was observed
in mice due to the blood collection.
Assay for a-N-acetylgalactosaminidase in mouse sera
The sera (100 tl) were precipitated using 70% saturated ammo-
nium sulphate. The precipitates were dissolved in 50 mm citrate
phosphate buffer (pH 6.0) and dialysed against the same buffer at
4°C overnight. The dialysates were made up to 0.5 ml in volume
and assayed for enzyme activity (Yamamoto et al, 1997a;
Yamamoto and Naraparaju, 1997). Substrate solution (300,1)
contained 50 mm citrate buffer (pH 6.0) and 5 ,umol of p-nitro-
phenyl-N-acetyl-a-D-galactosaminide. The reaction was initiated
by the addition of 500,l of the dialysed sample, was kept for
60 min at 37°C and was terminated by the addition of 200 pl of
10% TCA. After centrifugation, 500 ,l of 0.5 gM sodium
carbonate solution was added to the supernatant. The amount of
released p-nitrophenol was determined spectrophotometrically at
420 nm and expressed as nmol min-' per mg of serum protein.
Protein concentrations were determined by the Bradford method
(Bradford, 1976).
The background level of the enzyme activity measured in the
serum ofhealthy control mice ranged from 1 to 1.5 nmol min-1 mg.
This was due to the presence of x-galactosidase, which can
hydrolyse the same substrate as NaGalase (Yamamoto and
Naraparaju, 1997). Thus, the enzyme activities beyond that
of control mice were attributed to NaGalase released from
cancerous cells.
The photosensitizer administration to non-treated or tumour-
bearing mice kept in the dark showed no effect on the serum
NaGalase activity in these animals; for example the levels in mice
bearing advanced tumours with and without Photofrin treatment
(10 mg kg-', 24 h earlier - no light) were 7.52 ± 0.15 and
7.53 ± 0.1 (± s.d.) respectively.
RESULTS
Correlation between serum NaGalase activity and
tumour burden
Serum levels of NaGalase in non-treated mice bearing SCCVII
tumours of different size are shown in Figure lA. Blood for the
enzyme activity measurement was collected immediately before
the mice were killed, the tumours excised and the wet weight
determined. It can be seen that the serum NaGalase activity is
directly proportional to the tumourburden in the range between 10
and 200 mg. The linear fit shown in Figure 1 has the correlation
coefficient of0.95253 and suggests the rate ofNaGalase secretion
to be 0.046 nmol min-' mg-' per mg of tumour tissue. A similar
result was reported for nude mice transplanted with a human
squamous cell carcinoma KB (Yamamoto et al, 1997a).
Time course study of serum NaGalase activity after
tumour inoculation
Serum NaGalase levels in mice bearing SCCVII tumours
increased with time after tumour implantation (Figure iB).
Although the tumours became palpable at 4 days after inoculating
1 x 106 SCCVII tumour cells, the enzyme activity was already
detectable 24 h after the implanation. After an initial sharp
increase in the NaGalase levels during the first 3 days post-
implant, there appear to be less pronounced changes within the
next few days. This may reflect a retardation in tumour progres-
sion before the development of the vascular supply needed to
support the growth of larger tumour masses. Another slowing
down in the increase of NaGalase activity was observed at longer
time intervals post-implant, which correlated with signs oftumour
necrosis in this well-characterized tumour model.
British Journal ofCancer (1998) 77(6), 1009-1014 0 Cancer Research Campaign 1998Enzyme markerforcancer therapy 1011
SCCVII tumours non-treated
)
E
E
=
E
I
U
50 100 150
Tumour weight (mg)
300-
250-
200-
150-
100-
50
0-
200
0 2 4 6 8 10 12 14 16 18
Time after tumour implant (days)
0 2 4 6 8 10 12 14 16 18
Time after X-rays (days)
-5
-4
3
- 2
- 1
Pz
0
CD
_'5
-3
3
a
-5)
D
l<
Figure 2 Changes in serum activity of a-N-acetylgalactosaminidase in mice
bearing X-ray-treated SCCVII tumours. After irradiation (20 Gy), variations in
tumour volumes were recorded and blood samples for the enzyme analysis
taken at different time intervals. The tumour volume data represent means for
18 tumours, whereas those for enzyme activity are means for three or four
tumour-bearing mice. Bars represent s.d. 0, tumour volume; 0, enzyme
activity
volume. Necrosis became apparent with some regrowing tumours
as early as 10 days after treatment. As evidenced by the increasing
errorbars, some ofthe tumours regrew morerapidly than others. In
addition, 2 out of 18 mice (11%) had complete tumour ablation
(which was observed within 2 weeks after treatment), and 1 out of
18 mice remained tumour-free at 90 days after treatment.
Figure 1 Serum activity of a-N-acetylgalactosaminidase in SCCVII tumour-
bearing mice. The results from the enzyme assay are shown related to either
(A) tumour weight (blood samples collected immediately before the mice
were killed at different times after inoculation and their tumours excised for
wet weight measurement) or (B) time after tumour implantation. Symbols in
A represent readings from individual tumours, whereas those in B are means
(± s.d.) for three or four individual tumours. The linear regression line is
shown for the correlation of enzyme activity with tumour weight
NaGalase activity after tumour X-ray treatment
The effect of X-ray treatment of SCCVII tumours with a single
dose of20 Gy was examined by registering changes in tumour size
and serum levels of NaGalase. A gradual decline in the enzyme
activity was observed during the first 10 days after treatment (the
data points at 6 and 10 days after X-rays are significantly lower
than the initial value, P < 0.05) followed by a slow increase during
the next 7 days (Figure 2). By the end of this observation period,
the average serum NaGalase levels did not reach the values
measured at the time of X-ray irradiation. This was not in parallel
with the changes in average tumour volume, which (after a tempo-
rary arrest) increased between days 3 and 17 after treatment. As it
was established that the NaGalase activity is directly proportional
to viable tumour burden, this apparent increase in tumour size
cannot be attributed to the regrowth of cancerous cells. The factors
that most probably play a role are cellular/tissue oedema and
increased proportions of non-viable tissue in the total tumour
Effect of PDT on tumours reflected by serum NaGalase
activity
An alternative modality for effective tumour treatment is PDT. The
treated SCCVII tumours were of a similar size to those used for the
above-described X-ray treatment (approximately 50mm3). The
serum levels of NaGalase in mice bearing tumours exposed to
Photofrin-based PDT (resulting in approximately 50% cures)
markedly declined between 24 and 48 h after the photodynamic
light exposure (Figure 3A), which correlated with a visible disap-
pearance of tumour mass. The values for enzyme activity deter-
mined in the sera of mice showing no sign of tumour recurrence at
90 days after PDT treatment (defined as tumour cure) were not
significantly different from the measurement of samples from non-
treated tumour-free control mice. In contrast, highly elevated
NaGalase levels were found in mice with recurring tumours. The
blood for this measurement was taken when the regrowing tumours
reached four times the PDT-treated volume (22-28 days after treat-
ment, 8-9 days after the tumours became palpable again).
The effect of Photofrin-mediated PDT is dependent on the
photosensitizer and light doses. In the next series of experiments,
the Photofrin dose was kept constant while two light doses (55 and
110 J cm-2) were tested. The higher light dose is 100% curative,
whereas the lower one is only marginally curative for the EMT6
tumour model used. Blood samples were collected at 24, 48 and
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A similar analysis was performed on SCCVII tumours treated
with PDT with photosensitizer mTHPC, which is more potent
than Photofrin. The mTHPC administration (0.6 mg kg-', i.v.)
followed 24 h later by a light dose of 100 J cm-2 was 100% cura-
tive for SCCVII tumours. The results (Figure 4A) show a rapid
decline in serum NaGalase activity in treated mice, which
dropped to background levels within 48 h after photodynamic
light treatment. All the values shown in Figure 4 are statistically
different from the non-treated tumour-bearing mice (P < 0.01),
whereas the values at 48 and 96 h are significantly lower than that
at 32 h (P < 0.01).
Multiple NaGalase measurements in individual
PDT-treated mice
*
Non-treated 24 h 48 h Tumour Tumour
tumours post PDT post PDT recurrence cure
EMT6 tumour
Photofrin 10 mg kg
0 10 20 30 40 50 60 70
Time after PDT (h)
Figure 3 Serum x-N-acetylgalactosaminidase activity in mice after
treatment of tumours with Photofrin based PDT. Mice were bearing either
(A) SCCVII tumour (Photofrin 25 mg kg-'; tumours illuminated with 75 J cm-2)
or (B) EMT6 tumour (Photofrin 10 mg kg-'; tumours illuminated with 55 or
110 J cm-2). Blood was taken from mice at the indicated times after PDT.
With mice showing tumour recurrence the blood was collected when lesions
regrew to 4 x the PDT-treated volume, whereas those from cured mice were
taken at 90 days after PDT. Means (+s.d.) are shown for groups of 3-6 mice.
*Values statistically different from non-treated tumour-bearing mice (P < 0.01)
U, 55Jcm-2;, 110Jcm-2
72 h after PDT, i.e. during the time period of most intense tumour
destruction. The NaGalase activity dropped markedly in both
treatment groups at 24 h after light treatment, which is in accor-
dance with the observed complete tumour ablation observed after
both PDT doses (Figure 3B). However, further decline in the
NaGalase levels was more pronounced with the higher PDT dose.
The data for the high- and low-light-dose groups at 72 h after PDT
are statistically different (P < 0.05).
Mice bearing SCCVII tumours were treated with a PDT dose that
gives a 50% tumour cure (0.3 mg kg-' mTHPC, 100 J cm-2).
Multiple measurements of NaGalase activity were performed by
collecting 0.1 ml of blood from the tail vein of the same mice at
several time intervals after PDT. This time course study reveals
that the profiles ofthe enzyme activity in mice with cured tumours
compared with those in mice with recurring tumours are substan-
tially different (Figure 4B).
If the tumour therapy were successful, the NaGalase levels
dropped to < 1 nmol min-' mg-' protein and remained at back-
ground levels throughout the observation period (100 days after
PDT). In the case oftumourregrowth, the lesions became palpable
again at 15-17 days after PDT and these mice were killed at
20 days after PDT. At 9-12 days after PDT, the average serum
NaGalase level in non-cured mice was significantly higher
(P < 0.01) than that in cured mice (already predicting the outcome
of therapy 4-8 days before the visible tumour recurrence) and
increased steeply for the following 8-11 days.
DISCUSSION
The malignant-specific NaGalase specific activity is readily
demonstrated with precision in 100-,ul quantities of sera from the
cancer-bearing hosts. In nude mice bearing human squamous cell
carcinoma, serum NaGalase activity levels are directly propor-
tional to tumour weight (Yamamoto et al, 1997). In support ofthis
concept, the correlation between ascities tumour cell counts and
serum NaGalase in BALB/c mouse has been demonstrated (Koga
et al, 1996; Yamamoto and Naraparaju, 1997). The proportionality
of serum NaGalase to tumour burden enabled us to use serum
NaGalase as a prognostic index effectively during macrophage-
directed immunotherapy of human and murine cancers
(Yamamoto et al, 1997b; Yamamoto and Naraparaju, 1997). In a
course ofprotracted radiation therapy, the serum NaGalase activi-
ties of individual patients constantly decreased towards healthy
control level if the tumours are localized at the targeted lesion
(Yamamoto et al, 1996).
This serum NaGalase proportionality to tumour burden is more
distinct when tumours are surgically removed. A day after surgical
removal of primary tumours from cancer patients, NaGalase
activity suddenly decreased to near the tumour-free control level
(Yamamoto et al, 1997), suggesting that the half-life of NaGalase
is less than 24 h. This short half-life of the tumour marker is valu-
able for prognosis of the disease during various therapies. In the
present study, we thus studied time course analysis of serum
NaGalase after a single radiation dosage (20 Gy at 3.33 Gy min').
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Figure 4 Serum a-N-acetylgalactosaminidase activity in mice after
treatment of SCCVII tumours with mTHPC-based PDT. Mice received either
(A) 0.6 mg kg-' or (B) 0.3 mg kg-1 of mTHPC followed 24 h later by treatment
with light (100 J cm-2). The data points are based on either (A) means (+s.d.)
from three or four serum samples (single blood collection per mouse) or (B)
separate measurements for individual mice (represented by different
symbols) with multiple blood collections (two or four depending on tumour
cure or regrowth). The weights of recurring tumours at day 20 after PDT
(when these mice were killed) are indicated in the graph. The data from
cured mice are shown as open symbols connected with solid lines, and those
from non-cured mice are closed symbols connected with dotted lines 4, 6, 7,
8, days before tumour reappearance
Serum NaGalase activity decreased until 10 days with small devia-
tions (Figure 2), whereas tumour volume gradually increased after
a brief arrest for 3 days. This volume increase after the lethal chro-
mosomal damage suggests the persistence of metabolic activities
and necrosis for a prolonged period.
In contrast, another human tumourprognostic marker, prostate-
specific antigen (PSA), disappears from serum with a half-life of
between 2 and 3 days upon complete removal of the prostate
gland in the absence of metastasis (Osterling, 1991). However,
Ritter et al (1992) demonstrated in acomprehensive study that the
half-life of the PSA is about 2.6 months after radiation therapy.
Thus, in spite oflethally damaged genome, the cells are still meta-
bolically capable of producing PSA for an extremely prolonged
period (2.6 months) after radiation therapy. Therefore, it is not
feasible to prognose (predict) accurately the fate of the radiated
tumours with rate ofPSA decrease during radiation therapy.
The profiles of serum NaGalase activity in mice after the
treatment of SCCVll tumours with various PDT regimens reveal
differences in the kinetics of tumour cell killing and subsequent
regrowth. The results showed that tumour cell death occurs more
rapidly after PDT than with X-rays (Figure 3). Cell membrane
rupture, initiated by peroxidation offatty acid moiety of membra-
nous phospholipids (Kessel, 1996; Thomas et al, 1987; Kelley et
al, 1997), can be observed within several hours afterPDT, whereas
X-rays trigger a delayed cell death process originating in chromo-
somal damage. After PDT there is a rapid inflammation-mediated
removal of destroyed cells (Korbelik, 1996) as opposed to a
prolonged retention ofmetabolically active mortally affected cells
in X-ray-treated lesions. Nevertheless, these findings ascertain the
validity of serum NaGalase measurement for the assessment of
tumour response to different treatments. The information on the
extent of tumour destruction for lesions not assessable by the
clonogenic method will be ofassistance in investigating the under-
lying mechanism ofaction.
As shown with PDT-treated SCCVII tumours (Figure 4B),
elevated NaGalase levels predicted the regrowth of this rapidly
growing carcinoma up to 8 days before its visible recurrence. In
similarclinical situations, the time scale with slow-growing human
cancers would be considerably longer. With such information
available, oncologists could modify the intensity or nature oftreat-
ment during cancertherapy.
The present study and evidence accumulated from otherpreclin-
ical and clinical studies (Naraparaju et al, 1996; Yamamoto et al,
1997a; 1997b; Yamamoto and Naraparaju, 1997) suggest that
NaGalase has the potential to become a valuable diagnostic/
prognostic index and a powerful tool for monitoring the tumour
response to cancertherapy.
Other valuable information that can be derived from serum
NaGalase measurements is the indication on a patient's immune
status, as (as mentioned in the Introduction) this enzyme deglyco-
sylates serum Gc protein, thus impairing an important component
in the process of immune development (Yamamoto and Homma
1991; Yamamoto et al, 1996; 1997a; Yamamoto and Naraparaju,
1997). This is clearly evidenced by the fact that cancer patients
frequently die fromoverwhelming infection. Thepractice ofmoni-
toring serum NaGalase activity has already been implemented,
with a few hundred cancer patients undergoing either established
therapies (Yamamoto et al, 1996; 1997a) or experimental
immunotherapy with enzymatically generated Gc protein-derived
MAF (Naraparaju et al, 1996; Yamamoto et al, 1997b). Without
exception, the NaGalase activity in the blood of patients who
respond well gradually declined during the course of therapy and
dropped to background levels in those individuals that appeared to
be cured (Yamamoto et al, 1997b).
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